A clinical study to assess the efficacy of a new interactive toothbrush in the reduction of gingivitis and dental plaque
| ISRCTN | ISRCTN77960012 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN77960012 |
| Secondary identifying numbers | Clinical Protocol 2020101 |
- Submission date
- 02/09/2020
- Registration date
- 03/09/2020
- Last edited
- 12/01/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Oral Health
Plain English Summary
Background and study aims
Gingivitis (inflammation of the gums) represents perhaps the most common disease of the periodontium (the tissues that surround and support the teeth), with a majority of adolescents and adults with teeth affected worldwide. Various factors have been implicated in the extent or severity of gingivitis. Of these, the microorganisms (e.g. bacteria) in dental plaque are recognized as playing a prominent role. Without adequate oral hygiene (e.g. toothbrushing), plaque accumulation may be rapid and visible gingival inflammation occurs within a few days. Even with extreme plaque accumulation, thorough oral hygiene and mechanical plaque removal are reported to reduce gingivitis and restore health. Control of plaque is an essential element in effective oral hygiene programs. Oral hygiene devices (toothbrushes) are under continuous review for efficacy and safety, as new devices or improvements of features on existing devices are developed. The aim of this study is to evaluate and compare the effectiveness of a new interactive electric toothbrush with a sensitive brush head to a marketed regular manual toothbrush in the reduction of gingivitis and dental plaque over a 12-week period.
Who can participate?
Generally healthy adults with evidence of plaque and mild to moderate gingivitis
What does the study involve?
Participants will be randomly assigned to either the Test group (new interactive electrical toothbrush) or the Control group (regular manual toothbrush). Participants will use their assigned products with a regular toothpaste twice daily at home for the duration of the study.
Plaque measurements will be taken at the first visit (before and after brushing), week 1 and week 12 visits (both before brushing only). Gingivitis measurements will be taken at the first visit, week 1, and week 12 visits. The individual appointments at the first visit, week 1 and week 12 will be scheduled for about the same daytime for all three visits. Participants will be instructed to abstain from any oral hygiene for 12 hours before all visits.
What are the possible benefits and risks of participating?
The study is designed to assess if the participants in the Test group will experience an improvement in oral health. Participants will use the study products at home in place of their regular toothbrush and toothpaste. Products will be returned at the end of the study. The dentifrice which will be provided in this study is currently marketed. The risk from chemical hazard is negligible, or no greater than what would have been encountered during daily life. Also, both kind of toothbrushes are currently marketed. Toothbrushes are not anticipated to cause any serious or long-term effects on oral tissue including gingival recession. This study involves the use of toothbrushes as part of a normal oral hygiene routine. No behavior with incremental risk will be requested from participants. In addition, their participation will help in the development of products that aim to improve oral health. There will be no notable risks involved with participating.
Where is the study run from?
All Sum Research Ltd (Canada)
When is the study starting and how long is it expected to run for?
August 2020 to December 2020
Who is funding the study?
Procter and Gamble Company (USA)
Who is the main contact?
Dr Chhaju Ram Goyal, DDS
crgoyal@allsumrc.com
Contact information
Scientific
All Sum Research Center Ltd.
6635 Kitimat Rd. #36 & #37
Mississauga, Ontario
L5N 6J2
Canada
| Phone | +1 (0)905 812 1099 |
|---|---|
| crgoyal@allsumrc.com |
Study information
| Study design | Single-center randomized controlled examiner-blind two-treatment parallel study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised parallel trial |
| Study setting(s) | Home |
| Study type | Prevention |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
| Scientific title | A 12-week clinical study to compare a new power brush with a sensitive brush head to a manual toothbrush in the reduction of gingivitis and plaque |
| Study hypothesis | The objective of the study is to evaluate and compare the efficacy of a new interactive electrical brush with a sensitive brush head to a regular manual brush in the reduction of gingivitis and dental plaque over a 12-week period by using the Modified Gingival Index, the Gingival Bleeding Index and the Rustogi Modification of the Navy Plaque Index. |
| Ethics approval(s) | Approved 12/12/2019, Veritas IRB Inc. (8555 Transcanada Hwy., Suite 201, Montreal, Quebec, H4S 1Z6, Canada; +1 (0)514 337 0442; nhamzeh@veritasirb.com), ref: 16474-09:44:1710-12-2019 |
| Condition | Mild to moderate gingivitis |
| Intervention | Participants are stratified at baseline on tobacco use, mean gingivitis score, number of bleeding sites, and mean plaque index. Within these strata, participants are randomly assigned to either the Test group (new interactive toothbrush with sensitive brush head) or the Control group (marketed regular manual toothbrush). Participants are instructed to use the study products according to the manufacturer instructions (electrical toothbrush) or in their customary manner (manual toothbrush) at home twice daily (morning and evening) in place of their normal oral hygiene for the duration of the study (12 weeks). Gingivitis measurements are taken at baseline, week 1, and week 12 visits. Plaque measurements are taken at: baseline visit (pre- and post-brushing), week 1, and week 12 visits (both pre-brushing only). |
| Intervention type | Device |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | |
| Primary outcome measure | 1. Gingival inflammation and bleeding measured by Modified Gingival Index (MGI) and Gingival Bleeding Index (GBI) at baseline, week 1, and week 12 2. Dental plaque measured by Rustogi Modification of the Navy Plaque Index (RMNPI) at baseline (pre- and post-brushing), week 1, and week 12 (both pre-brushing only) |
| Secondary outcome measures | There are no secondary outcome measures |
| Overall study start date | 19/08/2020 |
| Overall study end date | 17/12/2020 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 100 |
| Total final enrolment | 100 |
| Participant inclusion criteria | 1. Give written informed consent prior to study participation and be given a signed copy of their informed consent form 2. Be at least 18 years of age and typically use a manual toothbrush 3. Be in good general health as determined by the investigator/designee based on a review/update of their medical history 4. Possess a minimum of 16 natural teeth with facial and lingual scorable surfaces 5. Have a Baseline whole mouth mean MGI score of at least 1.75 but not more than 2.5 6. Have a Baseline whole mouth pre-brushing RMNPI score of greater than 0.5 7. Have at least 20 but not more than 90 bleeding sites (sites with a score of 1 or 2 on the GBI index) for Baseline whole mouth mean 8. Agree not to participate in any other oral care study for the duration of this study 9. Agree to not to have any elective dentistry, including dental prophylaxis, until study completion and to report any non-study dentistry received at any time during the course of this study 10. Agree to refrain from using any non-study oral hygiene products for the study duration 11. Agree to return for all their scheduled visits and to follow all study procedures 12. Refrain from brushing their teeth or from performing any other oral hygiene procedure anytime within the 12 hours prior to Baseline Visit and agree to follow these same restrictions prior to all visits 13. Refrain from medicated lozenges, breath mints, eating, drinking*, chewing gum and using tobacco for at least 4 hours prior to this visit and agree to follow these same restrictions prior to all visits. *(Allowed small sips of water up until 45 minutes prior to their appointments) |
| Participant exclusion criteria | 1. A condition requiring the need for antibiotic premedication prior to dental procedures 2. Severe periodontal disease, including but not limited to, purulent exudates, generalized mobility, and/or severe recession 3. Teeth that are grossly carious, fully crowned, or extensively restored 4. Active treatment for the following conditions: periodontitis, cancer, or a seizure disorder 5. Report to be nursing or pregnant, or intend to become pregnant any time during the course of this study 6. Taking an antibiotic or using a chlorhexidine mouth rinse any time within the previous 2 weeks 7. Have any of the following: orthodontic appliances, removable partial dentures, peri/oral piercings, a pacemaker or other implanted device 8. Oral/gum surgery within the previous 2 months 9. A disease or condition that could possibly interfere with examination/procedures or with the subject’s safe completion of this study |
| Recruitment start date | 14/09/2020 |
| Recruitment end date | 18/09/2020 |
Locations
Countries of recruitment
- Canada
Study participating centre
Mississauga, Ontario
L5N 6J2
Canada
Sponsor information
Industry
8700 Mason-Montgomery Road
Mason
45040
United States of America
| Phone | +1 (0)513-622 1000 |
|---|---|
| timm.h@pg.com | |
| Website | http://www.pg.com/en_US/ |
"ROR" |
https://ror.org/04dkns738 |
Funders
Funder type
Industry
Government organisation / For-profit companies (industry)
- Alternative name(s)
- Procter & Gamble, PandG, The Procter & Gamble Company, P&G
- Location
- United States of America
Results and Publications
| Intention to publish date | 30/06/2022 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not expected to be made available |
| Publication and dissemination plan | Planned publication in a high-impact peer reviewed journal. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are not expected to be made available because if the raw data is available but not analyzed appropriately by qualified experts in the area, it may lead to misinterpretation of the results. Study protocol, statistical analysis plan, and other additional documents are not intended to become available online. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Poster results | 23/07/2021 | 12/01/2022 | No | No | |
| Poster results | 23/07/2021 | 12/01/2022 | No | No |
Editorial Notes
12/01/2022: Publication references added.
11/01/2022: The overall end date was changed from 31/12/2020 to 17/12/2020.
14/12/2021: The intention to publish date was changed from 31/12/2021 to 30/06/2022.
04/12/2020: The final enrolment number has been added.
02/09/2020: Trial's existence confirmed by Veritas IRB Inc.
